Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Annals of Hematology|June 4, 2025
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapyMarianna Gentilini, Beatrice Casadei, Cinzia Pellegrini, et al.
Cancers|October 13, 2021
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric ExperienceBeatrice Casadei, Lisa Argnani, Serafina Guadagnuolo, et al.
Cancers|April 30, 2021
Electrochemotherapy in Vulvar Cancer and Cisplatin Combined with Electroporation. Systematic Review and In Vitro StudiesAnna Myriam Perrone, Gloria Ravegnini, Stefano Miglietta, et al.
Hematological Oncology|October 31, 2012
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective studyPier Luigi Zinzani, Cinzia Pellegrini, Emanuela Merla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2010
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patientsPier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, et al.
American Journal of Hematology|April 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell LymphomaGabriele Gugliotta, Lisa Argnani, Martina Cantelli, et al.
Leukemia & Lymphoma|January 7, 2016
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient programPier Luigi Zinzani, Cinzia Pellegrini, Giuseppe Cerciello, et al.
Cancers|February 15, 2022
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela StudyBeatrice Casadei, Lisa Argnani, Alessandro Broccoli, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2026
Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE studyNicole Fabbri, Beatrice Casadei, Annalisa Chiappella, et al.
Hemasphere|November 18, 2022
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based TherapyLisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, et al.
Pageof 10